Levosimendan Carinopharm (Levosimendan)

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which strengthens heart muscle contraction without raising intracellular calcium. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that lowers both preload and afterload, thereby improving overall cardiac output.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, severity of heart failure, and response to therapy. Healthcare professionals set the infusion rate and duration according to established guidelines and individual patient needs.

The safety of levosimendan in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering combined inotropic and afterload‑reducing effects that can be advantageous in certain heart‑failure scenarios.

Levosimendan Carinopharm should be stored at 2‑8 °C, protected from light, and kept in its original packaging. The product must not be frozen or shaken. Before use, allow the solution to reach room temperature if required, and inspect for any particulate matter or discoloration.

Levosimendan is administered intravenously, typically as a continuous infusion after an optional loading dose. The infusion is given under close hemodynamic monitoring in a hospital setting, allowing clinicians to adjust the rate based on blood pressure, heart rate, and overall response.

The most serious risks include severe hypotension, ventricular tachyarrhythmias, myocardial ischemia, and rare allergic reactions. Continuous cardiovascular monitoring during infusion is essential to detect and manage these potential complications promptly.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, severe hypotension unresponsive to treatment, and those with significant obstructive cardiac outflow lesions. Caution is also advised in patients with severe renal or hepatic impairment, and it should be avoided in pregnancy unless absolutely necessary.